GTX Genetix Grp

RNS Number:1205D
AIM
17 May 2006


          ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2

ALL APPLICANTS MUST COMPLETE THE FOLLOWING:

COMPANY NAME:  Genetix Group plc

COMPANY ADDRESS:  Queensway, New Milton, Hampshire

COMPANY POSTCODE:  BH25 5NN

COUNTRY OF INCORPORATION:  England and Wales

COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED IN
ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:  Designs, develops and manufactures innovative
automated systems for use in cell biology, proteomics and genomics

DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to which
it seeks admission and the number and type to be held as treasury shares):  Current issued share capital of
71,698,688 ordinary shares of 50 pence each; and

a total of 1,130,480 ordinary shares of 50 pence each pursuant to a block listing application in respect of the
following share option schemes:

Genetix Group plc (Approved) 2000 Share Option Scheme - 463,667 ordinary shares

Genetix Group plc (Unapproved) 2000 Share Option Scheme - 467,000 ordinary shares

The Genetix Group plc Share Save Scheme - 199,813 ordinary shares



CAPITAL TO BE RAISED ON ADMISSION:  Transfer from the Official List, no fund raising

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:

John Christopher Morgan - Non-executive Chairman

Mark Antony Reid - Chief Executive

Andrew John Kellett - Finance Director

Professor Julian Francis Burke - Scientific Director

Dr. James Ferguson Hill - Non-executive Director

Peter Sinclair Jensen - Non-executive Director

PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL
BEFORE AND AFTER ADMISSION:

                          (Before and after Admission)

Mark Antony Reid                      59.3%

John Christopher Morgan                7.0%



Includes shareholdings of spouses

NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

ANTICIPATED ACCOUNTING REFERENCE DATE:  31 December

EXPECTED ADMISSION DATE: 2 June 2006

NAME AND ADDRESS OF NOMINATED ADVISER:

Piper Jaffray Ltd., First Floor, 18 King William Street, London EC4N 7US

NAME AND ADDRESS OF BROKER:

Piper Jaffray Ltd., First Floor, 18 King William Street, London EC4N 7US

DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT
THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

N/A - Transfer to AIM from the Official List, no admission document required

DATE OF NOTIFICATION:  17 May 2006

NEW/ UPDATE (see note):  Update

QUOTED APPLICANTS MUST ALSO COMPLETE THE FOLLOWING:

THE NAME OF THE AIM DESIGNATED MARKET UPON WHICH THE APPLICANT'S SECURITIES HAVE BEEN TRADED:

Official List of the London Stock Exchange

THE DATE FROM WHICH THE APPLICANT'S SECURITIES HAVE BEEN SO TRADED:

29 November 2000

CONFIRMATION THAT, FOLLOWING DUE AND CAREFUL ENQUIRY, THE APPLICANT HAS ADHERED TO ANY LEGAL AND REGULATORY
REQUIREMENTS INVOLVED IN HAVING ITS SECURITIES TRADED UPON SUCH A MARKET:

Confirmed

AN ADDRESS OR WEB-SITE ADDRESS WHERE ANY DOCUMENTS OR ANNOUNCEMENTS WHICH THE APPLICANT HAS MADE PUBLIC OVER THE
LAST TWO YEARS (IN CONSEQUENCE OF HAVING ITS SECURITIES SO TRADED) ARE AVAILABLE:

www.genetix.com

DETAILS OF THE APPLICANT'S STRATEGY FOLLOWING ADMISSION INCLUDING, IN THE CASE OF AN INVESTING COMPANY, DETAILS
OF ITS INVESTMENT STRATEGY:

To design, develop and manufacture innovative automated systems for use in cell biology, proteomics and genomics

A DESCRIPTION OF ANY SIGNIFICANT CHANGE IN FINANCIAL OR TRADING POSITION OF THE APPLICANT, WHICH HAS OCCURRED
SINCE THE END OF THE LAST FINANCIAL PERIOD FOR WHICH AUDITED STATEMENTS HAVE BEEN PUBLISHED:

There has been no significant change in the financial or trading position of the Company since 31 December 2005,
being the date of the Company's last financial period for which audited statements have been published

A STATEMENT THAT THE DIRECTORS OF THE APPLICANT HAVE NO REASON TO BELIEVE THAT THE WORKING CAPITAL AVAILABLE TO
IT OR ITS GROUP WILL BE INSUFFICIENT FOR AT LEAST TWELVE MONTHS FROM THE DATE OF ITS ADMISSION:

The directors of Genetix Group plc have no reason to believe that the working capital available to it or its
group will be insufficient for at least twelve months from the date of its admission

DETAILS OF ANY LOCK-IN ARRANGEMENTS PURSUANT TO RULE 7 OF THE AIM RULES:

None

A BRIEF DESCRIPTION OF THE ARRANGEMENTS FOR SETTLING THE APPLICANT'S SECURITIES:

CREST

A WEBSITE ADDRESS DETAILING THE RIGHTS ATTACHING TO THE APPLICANT'S SECURITIES:

www.genetix.com

INFORMATION EQUIVALENT TO THAT REQUIRED FOR AN ADMISSION DOCUMENT WHICH IS NOT CURRENTLY PUBLIC:

Available at www.genetix.com

A WEBSITE ADDRESS OF A PAGE CONTAINING THE APPLICANT'S LATEST ANNUAL REPORT AND ACCOUNTS WHICH MUST HAVE A
FINANCIAL YEAR END NOT MORE THEN NINE MONTHS PRIOR TO ADMISSION AND FULLY AUDITED INTERIM RESULTS WHERE
APPLICABLE.  THE ACCOUNTS MUST BE PREPARED ACCORDING TO UK OR US GAAP OR INTERNATIONAL ACCOUNTING STANDARDS:

www.genetix.com

THE NUMBER OF EACH CLASS OF SECURITIES HELD IN TREASURY:

None





                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AIMUBVARNKRVAAR

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Aug 2024 to Sep 2024

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Sep 2023 to Sep 2024